Hospira, Inc. (HSP) Appoints Richard Davies as Chief Commercial Officer
Down)
Hospira, Inc. (NYSE: HSP) today announced that Richard Davies has been named senior vice president and chief commercial officer. In this role, he will be responsible for developing and executing Hospira's global commercial strategies and delivering profitable revenue growth across the company's product portfolio. Mr. Davies will join Hospira Feb. 2 and serve as a member of Hospira's senior leadership team, reporting to F. Michael Ball, chief executive officer.
Mr. Davies, 50, brings to Hospira more than 20 years of diverse strategic and operational experience gained through a variety of commercial management positions and across a range of products and technologies. Most recently, he served as vice president and general manager, Japan, Asia Pacific and Latin America, for Amgen, where he was responsible for establishing Amgen's business in the region as well as supporting its strategy development for emerging markets overall. During his eight years at Amgen, he led the company's commercial organizations in Central/Eastern Europe and Australia, and also served as vice president of U.S. sales for the immunology franchise. Prior to joining Amgen, Mr. Davies spent 13 years at Eli Lilly and Company in increasing roles of commercial responsibility, including general country management.
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
Mr. Davies, 50, brings to Hospira more than 20 years of diverse strategic and operational experience gained through a variety of commercial management positions and across a range of products and technologies. Most recently, he served as vice president and general manager, Japan, Asia Pacific and Latin America, for Amgen, where he was responsible for establishing Amgen's business in the region as well as supporting its strategy development for emerging markets overall. During his eight years at Amgen, he led the company's commercial organizations in Central/Eastern Europe and Australia, and also served as vice president of U.S. sales for the immunology franchise. Prior to joining Amgen, Mr. Davies spent 13 years at Eli Lilly and Company in increasing roles of commercial responsibility, including general country management.
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
You May Also Be Interested In
- I.V. Clinical Integration Helps Deliver Safety, Efficiency And Financial Benefits; Hospira Shares Snapshot Of Results, Process
- Barclays Maintains an 'Equalweight' on Brookfield Properties (BPO); Corporate Evolution
- Rosetta Genomics (ROSG) Names New CFO
Create E-mail Alert Related Categories
Management ChangesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
